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The outbreak of 2019 novel coronavirus (coronavirus
disease 2019 [COVID-19]) has been declared a pandemic
spread by the WHO on March 11, 2020. Some countries
have been hit earlier and with lightning violence, leading to
the collapse of health facilities and putting public health to
test. This epidemiologic and social emergency puts at risk
of undertreatment not only patients with acute infections
but also health care pathways for other diseases. Diag-
nostic tests and hospital facilities are largely used for pa-
tients with COVID-19, and most resources are invested in
this field. Nevertheless, it is our duty, as surgical specialists,
not to forget our patients, especially patients with cancer.
What is happening to the lung cancer pathways of referral
and treatment? For how long do we have to face this
emergency? What will be the cost in terms of lung cancer-
related death in this scenario?
It is a management and ethics dilemma, and the
answer is not easy to find in the absence of evidences.1
We established in our Lung Cancer Unit a new risk
stratification for lung cancer progression and COVID-19
infection (Table 1). We matched both and elaborated a
new integrated stratification risk to prevent adverse
outcomes from COVID-19 after oncologic treatment
(Table 2).
We promote new therapeutic options on the basis of
the integrated classification as follows:
Stage I: Anatomical lung resection, the early stages
allow definitive oncologic treatment without the need for
further hospital admission or adjuvant treatments (low
risk of infection).
Stage IIa: Anatomical lung resection (low risk of
infection).
Stage IIb: Discuss with the patient the possibility of a
follow-up (up to 3 mo) before a definitive therapeutic
decision after the epidemiologic peak has been over-
come. Personalized treatments are evaluated.
Stage III: Consider exclusive nonsurgical treatments.
This algorithm of care tries to balance the risk of
dying from cancer with the risk of incurring a potentially
fatal infection after major surgery or any oncologic
treatment. It is partially evidence-based and mostly on
the basis of common sense and on the need for sup-
porting the current emergency without forgetting our
patients.
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COVID-19, coronavirus disease 2019.
COVID-19, coronavirus disease 2019.
Table 2. New Integrated Risk Classification
Stage
I
Low risk of progression and low risk of COVID-19 infection
Stage
IIa
High risk of progression and low risk of COVID-19 infection
Stage
IIb
Low risk of progression and high risk of COVID-19 infection
Stage
III
High risk of progression and high risk of COVID-19
infection
COVID-19, coronavirus disease 2019.
COVID-19, coronavirus disease 2019.
Address for correspondence: Stefano Cafarotti, Lung Cancer Center
Oncology Institute of Southern Switzerland (IOSI) and EOC Thoracic
Surgery, Ospedale Regionale di Bellinzona e Valli, 6500 Bellinzona,
Switzerland. E-mail: Stefano.cafarotti@eoc.ch
ª 2020 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. This is an open access article under the




Journal of Thoracic Oncology Vol. 15 No. 6: e81-e99
